These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12243512)

  • 21. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating levels of HER-2/neu oncoprotein in breast cancer.
    Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
    Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
    Kumpulainen EJ; Keskikuru RJ; Johansson RT
    Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
    BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
    D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
    Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum c-erB-2 levels in monitoring of operable breast cancer patients.
    Imoto S; Kitoh T; Hasebe T
    Jpn J Clin Oncol; 1999 Jul; 29(7):336-9. PubMed ID: 10470658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum c-erbB-2 in breast cancer patients.
    Watanabe N; Miyamoto M; Tokuda Y; Kubota M; Ando Y; Tajima T; Mitomi T
    Acta Oncol; 1994; 33(8):901-4. PubMed ID: 7818922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of CA 15-3 serum levels in breast cancer patients.
    Skrzydlewski Z; Niklinski J; Kiluk S; Kiluk M; Musiatowicz B; Zaremba E; Skrzydlewska E; Klepacki A
    Minerva Chir; 1997 Mar; 52(3):251-4. PubMed ID: 9099053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
    Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.
    Schöndorf T; Hoopmann M; Warm M; Neumann R; Thomas A; Göhring UJ; Eisberg C; Mallmann P
    Clin Chem; 2002 Aug; 48(8):1360-2. PubMed ID: 12142395
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
    Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF
    Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
    Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
    Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
    Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer.
    Gonssaud B; Goussot V; Berriolo-Riedinger A; Saïtta-Aribau E; Coutant C; Cochet A; Fumoleau P; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):421-429. PubMed ID: 28751287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.